lum-201 (ibutamoren); growth hormone; pghd

Andrew Dauber, M.D., Chief of Endocrinology, Children's National Medical Center, Washington, D.C. discusses the data and potential of LUM-201 for children living with moderate pediatric growth hormone deficiency

https://lifescievents.com/event/lumos-2/

Rick Hawkins, CEO and chairman of Lumos Pharma, discusses the company’s late-stage development of a small molecule for the treatment of pediatric growth hormone deficiency (PGHD). This innovative oral mini tablet aims to revolutionize the current standard of care, which involves daily injections...

The video discusses pediatric growth hormone deficiency (PGHD) and its management, particularly through daily or weekly growth hormone injections. It explains the diagnosis process, the two categories of patients (moderate and severe), and the different treatment options available, including a...

The OraGrowtH212 trial is a global study involving 80 patients in four arms, testing three different doses of a new drug compared to the standard dose of growth hormone. The study aims to measure catchup growth over an extended period, with promising interim results indicating comparable growth...

https://lifescievents.com/event/lumos/

https://www.iheart.com/podcast/256-rarecast-31040095/episode/lumos-hopes-its-oral-alternative-to-112339601/ Growth hormone deficiency is a rare condition that is the result of inadequate secretion of growth hormone from the pituitary gland. Though recombinant human growth hormone has long been...